BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Phylogica Ltd. Licenses Technology to Janssen Biotech Inc.


1/4/2012 8:44:22 AM

PERTH, AUSTRALIA--(Marketwire - January 04, 2012) - Phylogica Ltd (ASX: PYC) (XETRA: PH7), a leading Australian peptide drug discovery company, announced today a Collaboration and Option agreement with Janssen Biotech, Inc. to discover new classes of drugs derived from Phylogica's Phylomer® peptide platform.

In the initial stage of the collaboration, Phylogica will identify cell-penetrating Phylomer® peptides. Under the terms of the agreement, Janssen could develop Phylomer®-based drug candidates and has the option to expand the scope of the collaboration to include additional cell-specific Phylomers® for the development of a further ten drug candidates.

Under the terms of this multi-product agreement, Phylogica will receive an initial technology access fee as well as research funding over the first 18 months of the collaboration. Pending ongoing discussions with Janssen regarding commercial terms, Phylogica could receive further research funding, license fees, milestone payments and royalties on worldwide sales.

Dr. Paul Watt, Phylogica's Chief Executive Officer, said: "We are delighted to be working with Janssen, which adds to our growing list of partners. This deal reflects our commitment to exploit the potential of Phylomers to address challenging disease targets with the aim of delivering new standards of care for patients. We look forward to working in partnership with Janssen to advance multiple Phylomer-based drug candidates. This agreement provides further validation of our world-leading Phylomer technology for peptide drug discovery."

About Phylogica
Phylogica Limited (ASX: PYC) is a biotechnology company based in Perth, Australia, and Oxford, UK, with a world-class drug discovery platform harnessing the rich biodiversity of nature to discover novel peptide therapeutics. The Company was incorporated in 2001 as a spin out from the Telethon Institute for Child Health Research (Perth, Australia) and the Fox Chase Cancer Centre (Philadelphia, USA). The Company's drug discovery platform is based on its proprietary Phylomer® libraries of natural peptides, which have been optimised by evolutionary selection to have stable drug-like structures. Phylogica offers fully integrated drug discovery services to the pharmaceutical industry utilising its Phylomer® libraries and proprietary screening technologies. Its current partners include Roche, MedImmune (the worldwide biologics arm of AstraZeneca) and Pfizer.

About Phylomer® Peptides
Phylomer peptides are derived from biodiverse natural sequences, which have been selected by evolution to form stable structures, which can bind tightly, and specifically to disease associated target proteins, both inside and outside cells. Suitable targets for blockade by Phylomers include protein interactions that promote multiple diseases, such as infectious diseases, cancer, autoimmunity and heart disease. Phylomer peptides can have drug-like properties, including specificity, potency and thermal stability, and are capable of being produced by synthetic or recombinant manufacturing processes. Phylomer peptides are also readily formulated for administration by a number of means, including parenteral or intranasal delivery approaches.


For further information, please contact:
Nick Woolf
CFO & VP, Corporate Development
Tel: +61 417 986 005
nwoolf@phylogica.com

Rudi Michelson
Monsoon Communications
Tel + 61 3 9620 3333



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES